Treats benign prostatic hyperplasia. ANDA 79060, held by Aurobindo Pharma. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 79060 (Alfuzosin Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Aug 30, 2012, with 5 approved supplements and 0 published complete response letters.
Alfuzosin hydrochloride extended-release tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG ยท tablet, extended release;oral | Alfuzosin Hydrochloride | Rx |
| Jul 1, 2026 | Supplement 20Manufacturing | Approved | None posted |
| Sep 15, 2022 | Supplement 13Labeling ยท Standard review | Approved | None posted |
| Dec 7, 2018 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Jan 14, 2015 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Jan 14, 2015 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Aug 30, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters